Delivery Order SPE2DB20D1100-SPE2DB25FC0E8

Award Date 4/29/25
Potential Completion Date 5/20/25
Potential Value $120K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $120,192.80, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, which is a Delivery Order, provides the DLA with OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC...
This federal contract award, valued at $120,192.80, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication, to support military healthcare programs. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $48,077.16, is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract is a Firm Fixed Price Delivery Order with a period of performance ending on January 28, 2025. The contract was not set aside for any specific business category. In addition to this delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $48,077.16, is a delivery order for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract has an ultimate completion date of February 28, 2025 and is a firm fixed-price arrangement. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the...
This federal contract award, valued at $87,447.60, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Firm Fixed Price Delivery Order for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract has an ultimate completion date of August 24, 2022. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a federal contract award issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order with a firm fixed price of $48,077.16 and a period of performance through May 14, 2025. The contract provides for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty pharmaceutical product. This contract is not set-aside and was competitively awarded. AmerisourceBergen Drug Corp...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $12,019.28 Firm Fixed Price contract is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract has an ultimate completion date of February 13, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distribution and healthcare solutions provider. The contract has an award value of $12,019.28 and is a Firm Fixed Price Delivery Order, with a completion date of February 27, 2025. The contract covers the procurement of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty pharmaceutical product. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) valued at...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract, valued at $47,834.16, is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract is a Firm Fixed Price Delivery Order with a completion date of January 8, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This federal contract award, valued at $72,115.74, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Firm Fixed Price Delivery Order for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a medical product. The contract has an ultimate completion date of April 14, 2025 and was awarded on March 24, 2025. There is no set-aside designation associated with this contract....
  • SPE2DB20D1100
    Indefinite Delivery Contract
  • SPE2DB20D1100-SPE2DB25FC0E8
    Delivery Order

This federal contract award, valued at $120,192.80, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is a delivery order (SPE2DB20D1100|SPE2DB25FC0E8) for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty pharmaceutical product. The contract is a firm fixed-price arrangement with a period of performance through May 20, 2025.

AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00 (SPE2DX), which provides a comprehensive global pharmaceutical support vehicle through December 2026. This IDC enables the company to supply a wide range of pharmaceutical products and medical supplies to support military and other government healthcare programs. The contract award described is not designated as a set-aside and represents open competition.

Generated 7/29/25, 10:04 AM